Back to Search
Start Over
Pharmacotherapy for the Treatment of Overweight and Obesity in Children, Adolescents, and Young Adults in a Large Health System in the US.
- Source :
-
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2020 May 13; Vol. 11, pp. 290. Date of Electronic Publication: 2020 May 13 (Print Publication: 2020). - Publication Year :
- 2020
-
Abstract
- Lifestyle modifications focused on diet, physical activity, and behavior have a modest impact on weight reduction in children, adolescents, and young adults (YA) with overweight and obesity. Several anti-obesity medications (AOMs) have been approved by the Food and Drug Administration (FDA) for use among adult patients with a body mass index (BMI) ≥27 kg/m <superscript>2</superscript> and at least one obesity-related illness. However, only two FDA-approved AOMs are available for use in children and adolescents, which leads to the frequent off-label use of adult AOMs among this population. We sought to investigate current prescribing patterns of AOMs from school age through to young adulthood in a large unified health system. Using a centralized clinical data registry containing the health data of ~6.5 million patients, individuals aged 5-25 years old with overweight and obesity who were taking one of eight commonly prescribed AOMs from 2009 to 2018 were extracted. A total of 1,720 patients were identified, representing 2,210 medication prescribing instances. The cohort was further stratified as children (5-12 years old), adolescents (13-18 years old), and YA (19-25 years old). The mean BMI at the time of medication initiation was 34.0, 39.1, and 39.6 kg/m <superscript>2</superscript> , respectively, which corresponded to a BMI z -score (BMIz) of 2.4 and 2.3 for children and adolescents, respectively. Metformin was the most commonly prescribed medication across all ages, including off-label use for weight-loss among children and adolescents. The most commonly off-label prescribed AOM among YA was topiramate. Multivariable analyses demonstrated phentermine was the most effective AOM, with a 1.54% total body weight among YA ( p = 0.05) and a 0.12 decrease in BMIz among adolescents ( p = 0.003) greater final weight loss when compared to the respective overall frequency-weighted means. Our study demonstrates a statistically significant weight loss among adolescents and young adults on select pharmacotherapy. The small magnitude of this effect should be interpreted carefully, as it is likely an underestimate in the absence of a true control group. Pharmacotherapy should therefore be considered in conjunction with other multimodal therapies such as lifestyle modification and metabolic and bariatric surgery when treating overweight and obesity.<br /> (Copyright © 2020 Czepiel, Perez, Campoverde Reyes, Sabharwal and Stanford.)
- Subjects :
- Adolescent
Adult
Child
Child, Preschool
Diet
Exercise
Female
Follow-Up Studies
Humans
Life Style
Male
Obesity metabolism
Obesity pathology
Overweight metabolism
Overweight pathology
Prognosis
Retrospective Studies
Young Adult
Anti-Obesity Agents therapeutic use
Body Mass Index
Obesity drug therapy
Overweight drug therapy
Weight Loss
Subjects
Details
- Language :
- English
- ISSN :
- 1664-2392
- Volume :
- 11
- Database :
- MEDLINE
- Journal :
- Frontiers in endocrinology
- Publication Type :
- Academic Journal
- Accession number :
- 32477270
- Full Text :
- https://doi.org/10.3389/fendo.2020.00290